To evaluate the efficacy and safety of Tirzepatide in T2DM, Karagiannis et al. [10] carried out a meta-analysis which showed that in comparison to the placebo, GLP1 receptor agonist (GLP1RA), and basal insulin, Tirzepatide demonstrated a dose-dependent superiority in glycaemic control assessed through HbA1c. Here, GLP1R is linked to type 2 diabetes mellitus.